We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Syntonix Pharmaceuticals Inc., based in Waltham, and German company Boehringer Ingelheim have entered into a collaboration to optimize certain Boehringer Ingelheim therapeutic peptides for inhalation, using Syntonix's SynFusion and Transceptor technologies.
Zimbabwe is to spend ZWD30bn (US$1.2mn) providing ARV treatments for public health facilities in an attempt to combat the growing HIV/AIDS crisis in the country.
Retail drug sales in the leading three markets in Latin America reached US$15.22bn -- an increase of 18% -- in the 12 months to August 2005, according to recently-released IMS Health data.
BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd., its parent company, the exclusive worldwide rights except Asia to develop and commercialize Anti-Fibroblast Growth Factor 8 (FGF8) monoclonal antibody, a potential new treatment for breast, ovarian and prostate cancers.
LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE) ("LAB"), an integrated drug development company with subsidiaries focused on developing therapies for the inhalation market and on providing contract research services, today announced that LAB Pharma, it's drug development subsidiary headquartered in Finland, has secured approximately $2.22 million (1.55 million euros) to support product development.
CepTor Corporation (OTCBB:CEPO), a development-stage biopharmaceutical company focusing on cell targeted therapeutic products for neuromuscular and neurodegenerative diseases, today announced that it will receive a $1.5 million milestone payment from JCR Pharmaceuticals of Japan upon filing an Investigational New Drug (IND) application for Myodur (C-101) in muscular dystrophy.
Stressgen Biotechnologies (TSX: SSB) today announced that it has received a favorable decision in its patent challenge by Antigenics from an Opposition Division of the European Patent Office that maintained the Company's European Patent EP-B1 1,002,110 in amended form.
MetaMorphix, Inc. of Beltsville, Maryland has announced that it is in the process of closing its Canadian subsidiary, MetaMorphix, Canada, Inc. located in Saskatoon, Saskatchewan Canada.